Evaluating vibegron for the treatment of overactive bladder

Introduction Vibegron is a very selective new beta 3-adrenergic receptor agonist introduced recently to clinical practice for OAB patients, which offers an alternative option for to antimuscarinic drugs. Areas covered This review presents the current knowledge concerning the mechanism of action, pharmacokinetics, and pharmacodynamics of vibegron. Moreover, it presents an overview of preclinical and phase II and phase III clinical studies on the efficacy, tolerability, and safety of this agent in patients suffering from OAB. Expert opinion Clinical studies confirmed efficacy and safety of vibegron in OAB patients. Vibegron differ from well-known mirabegron with regards to its pharmacological pro?le because it is metabolized independently from CYP3A4, 2D6, or 2C9 and therefore is less likely to cause a drug-drug interaction. Moreover, since this drug does not penetrate the blood-brain barrier, it could become the drug of choice in OAB patients with cognitive impairment. These properties have paved the way in near future for better-tailored treatments for OAB patients.

Automated summary

Vibegron, a new beta 3-adrenergic receptor agonist, has shown efficacy and safety in clinical studies for OAB patients. Different from mirabegron, Vibegron has a unique pharmacological profile that reduces the risk of drug-drug interactions and is suitable for OAB patients with cognitive impairment. These characteristics may lead to better-tailored treatments for OAB patients in the future.